Travere Therapeutic TVTX
$47.00 −$1.30 (-2.69%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $47.29 +0.62%
Open$48.09
Prev close$48.30
Day range$46.90 – $49.35
Volume1.33M
Market cap$4.51B
P/E (TTM)–
Dividend yield–
TVTX Stock News
Headlines matching Travere Therapeutic or the TVTX ticker, most recent first.
- Guggenheim Maintains Travere Therapeutic(TVTX.US) With Buy Rating, Raises Target Price to $89 Positive
- BofA Securities Maintains Travere Therapeutic(TVTX.US) With Buy Rating, Maintains Target Price $71
- Wedbush Maintains Travere Therapeutic(TVTX.US) With Buy Rating, Raises Target Price to $76 Positive
- Travere Therapeutics: Eric Dube, Ph.D., to Step Down as Pres and CEO in Dec TVTX
- A Quick Look at Today's Ratings for Travere Therapeutic(TVTX.US), With a Forecast Between $70 to $90
- J.P. Morgan Maintains Travere Therapeutic(TVTX.US) With Buy Rating, Raises Target Price to $90 Positive
- A Quick Look at Today's Ratings for Travere Therapeutic(TVTX.US), With a Forecast Between $68 to $85
- A Quick Look at Today's Ratings for Travere Therapeutic(TVTX.US), With a Forecast Between $62 to $85
- Piper Sandler Maintains Travere Therapeutic(TVTX.US) With Buy Rating, Raises Target Price to $68 Positive
- Analysts Offer Insights on Healthcare Companies: Travere Therapeutics (TVTX), Maze Therapeutics, Inc. (MAZE) and Immunome (IMNM)
- CCORF Maintains Travere Therapeutic(TVTX.US) With Buy Rating, Maintains Target Price $70
- Evercore Maintains Travere Therapeutic(TVTX.US) With Buy Rating, Raises Target Price to $78 Positive
- Stifel Maintains Travere Therapeutic(TVTX.US) With Hold Rating, Maintains Target Price $62
- CCORF Maintains Travere Therapeutic(TVTX.US) With Buy Rating, Raises Target Price to $62 Positive
- TD Cowen Maintains Travere Therapeutic(TVTX.US) With Buy Rating, Maintains Target Price $60
No comments yet — be the first to weigh in on TVTX.
Sign in to join the discussion.